Plain-English translation of NCT07230483 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a follow-up study for people with atopic dermatitis (eczema) who already participated in an earlier trial of . Researchers want to see how safe and effective this medication continues to be when patients take it over a longer period of time. You would be joining a study across multiple research centers to help doctors understand whether this treatment remains a good option for managing eczema symptoms.
Early testing showed promise for this medication, but doctors need to know whether it stays safe and works well over months and years of use. This longer study will help determine if the medication is truly reliable for people managing atopic dermatitis.
You likely qualify if…
You likely don't qualify if…
Since this is a follow-up to an earlier study you already completed, you would continue taking the medication and visiting the research center for check-ups to monitor how well it works and whether you experience any side effects. The study team will evaluate your skin condition and overall health at regular visits over the long term to build a complete picture of how safe and effective this treatment is.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Sponsor
Keymed Biosciences Co.Ltd
Enrollment target
~246 participants
Started
December 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qian Jia
Peking University People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.